Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca raises earnings guidance as profit margins improve
02:45am, Thursday, 10'th Nov 2022
AstraZeneca PLC (LSE:AZN) has increased its earnings guidance after a strong quarter during which EPS grew by 70% at constant exchange rates. The Anglo-Swedish drugs giant says it now expects 2022 cor
AstraZeneca lifts guidance after forecast-beating profit sales
02:45am, Thursday, 10'th Nov 2022
By Cecilia Butini
AstraZeneca tops quarterly estimates buoyed by cancer drug sales
02:12am, Thursday, 10'th Nov 2022
AstraZeneca on Thursday topped analysts' expectations for third-quarter profit and revenue, helped by sales of its key cancer drugs, and raised its full-year adjusted earnings forecast.
AstraZeneca Q3 Preview: Can Shares Stay Strong?
06:48pm, Wednesday, 09'th Nov 2022
AZN shares have been a bright spot in an otherwise dim market in 2022, up nearly 8% and widely outperforming the general market.
AstraZeneca receives backing for new rescue inhaler
03:37am, Wednesday, 09'th Nov 2022
AstraZeneca PLC (LSE:AZN) looks set to launch the world's first rescue medication for asthma sufferers that also reduces the underlying inflammation associated with ‘exacerbations' of the condition.
Most Promising Pharmaceutical Company During A Recession
06:06pm, Monday, 07'th Nov 2022
AstraZeneca's revenue was $10,771 million in the 2nd quarter of 2022, showing a 31% increase from the previous year. Over the past three quarters, a slew of AstraZeneca's medicines have received regul
Top defensive stocks for a volatile market, with Thornburg's Jason Brady
02:33pm, Monday, 07'th Nov 2022
Jason Brady, president and CEO of Thornburg Investment Management, joins ‘The Exchange' to discuss why big-cap tech stocks like Apple, Microsoft, Amazon and Meta are still meaningful despite poor pe
AstraZeneca's Beyfortus gets EU approval for RSV in infants
03:46am, Friday, 04'th Nov 2022
AstraZeneca PLC (LSE:AZN) and Sanofi's Beyfortus (nirsevimab) immunisation has been approved in the EU for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (L
AstraZeneca password lapse exposed patient data
12:00pm, Thursday, 03'rd Nov 2022
Pharmaceutical giant AstraZeneca has blamed “user error” for leaving a list of credentials online for more than a year that exposed access to sensitive patient data. Mossab Hussein, chief security
AstraZeneca shares will get lift from heartburn litigation closure, says Citi
08:43am, Tuesday, 01'st Nov 2022
AstraZeneca can get a boost from the probability that it will close out its US kidney damage lawsuit in New Jersey prior to the first bellwether case in March 2023, according to Citi. The UK pharma is
AstraZeneca: Acquisitions And Some Thoughts About Biotech Investing
02:35pm, Sunday, 30'th Oct 2022
AstraZeneca plans to grow beyond 2025 by building its innovation pipeline. Investors in the target benefit when a big pharma company acquires an emerging company.
AstraZeneca says advanced trial of breast-cancer drug Capivasertib meets primary endpoints
02:51am, Wednesday, 26'th Oct 2022
AstraZeneca PLC said Wednesday that Capivasertib plus Faslodex significantly improved progression-free survival when compared with Faslodex combined with a placebo in a Phase 3 trial in advanced hormo
AstraZeneca trial of Fasrena fails to meet one of two dual-primary endpoints
04:24am, Tuesday, 25'th Oct 2022
AstraZeneca PLC (LSE:AZN) reported an unsuccessful phase-three clinical for a new treatment to help with a condition of the oesophagus. The late-stage ‘MESSINA' study of the company's Fasrena drug i
AstraZeneca says Imjudo-Imfinzi combination approved in advanced liver cancer in US
02:41am, Monday, 24'th Oct 2022
AstraZeneca PLC (LSE:AZN) announced that the US Food and Drug Administration (FDA) has approved the company's Imjudo (tremelimumab) drug in combination with Imfinzi (durvalumab) for treatment of ad
AstraZeneca earnings to fall due to lower sales and higher costs
10:55am, Friday, 21'st Oct 2022
Credit Suisse expects AstraZeneca core average earnings per share will fall 5.5% after reduced sales and higher operating costs. AstraZenenca also is no longer ranked number one in Credit Suisse's Pha
